trending Market Intelligence /marketintelligence/en/news-insights/trending/5y6ntpjs2zJbwC_wkG9MCg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck KGaA shifts rights to CAR-T therapies to Intrexon in $150M share agreement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck KGaA shifts rights to CAR-T therapies to Intrexon in $150M share agreement

Merck KGaA and Intrexon Corp. have altered a 2015 license agreement for the joint development of chimeric antigen receptor T-cell, or CAR-T, therapies.

In March 2015, Merck and Intrexon agreed to collaborate to develop and commercialize CAR-T therapies, which take a person's own immune cells and modifies them to fight cancer cells when infused back into the body. The collaboration utilizes Intrexon's proprietary RheoSwitch Therapeutic System and the Sleeping Beauty non-viral gene integration technology.

Under the new agreement, Darmstadt, Germany-based Merck will receive $150 million in Intrexon shares in exchange for exclusive CAR-T development rights. Precigen, a wholly owned subsidiary of Intrexon, will continue developing the CAR-T technology. The agreement is subject to closing conditions.

Additionally, Germantown, Md.-based Intrexon will issue a $25 million note to Merck, which can be converted to shares of either Precigen or Intrexon.